Nanomedicine Therapies for Pediatric Diseases
WIREs Nanomedicine and Nanobiotechnology · 2024
DOI: 10.1002/wnan.1996 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, 2024. Verfasst von Shicheng Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Northeastern University, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Nanomedicine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
In 2020, the top 10 causes of death among children and adolescents between the ages of 1 and 19 years old included cancer, congenital anomalies, heart disease, and chronic respiratory disease; all these conditions are potentially treatable with medical intervention. However, children exhibit specific physiological and developmental characteristics that can significantly impact drug pharmacokinetics, pharmacodynamics, and safety profile. These factors illustrate the importance of a heightened focus on pediatric drug development. Traditional drugs lack proper circulation, permeability, targeting, accumulation, and release, and they often require dose adjustments or modifications, which can result in suboptimal therapeutic outcomes and increased risks of adverse effects in pediatric patients. Nanomedicines have emerged as efficient drug delivery systems because of their unique properties, which can improve the solubility and stability of drugs by encapsulating them in different forms of nanoparticles. This review discusses the challenges of pediatric therapy, and the current state of nanomedicines for pediatric diseases in terms of Food and Drug Administration‐approved nanomedicines, the types of diseases treated or diagnosed, and preclinical studies that have the potential to be translated to the clinic. In summary, nanomedicine holds significant potential for addressing the unique and pressing challenges associated with diagnosing and treating pediatric diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Engineering, Northeastern University, Boston, Massachusetts, USA.
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA.
- Cancer Nanomedicine Co-Ops for Undergraduate Research Experience (CaNCURE), Northeastern University, Boston, Massachusetts, USA.
- Department of Physics, Northeastern University, Boston, Massachusetts, USA.
- Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Bioengineering, Northeastern University, Boston, Massachusetts, USA.
ORCID-Profile: Shicheng Yang, Kushi Aggarwal, Jillian Jurczyszak, Needa Brown, Srinivas Sridhar
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Yang, S., Aggarwal, K., Jurczyszak, J., Brown, N., & Sridhar, S. (2024). Nanomedicine Therapies for Pediatric Diseases. WIREs Nanomedicine and Nanobiotechnology. https://doi.org/10.1002/wnan.1996
Vancouver
Yang S, Aggarwal K, Jurczyszak J, Brown N, Sridhar S. Nanomedicine Therapies for Pediatric Diseases. WIREs Nanomedicine and Nanobiotechnology. 2024. doi:10.1002/wnan.1996
BibTeX
@article{Yang2024,
author = {Yang, Shicheng and Aggarwal, Kushi and Jurczyszak, Jillian and Brown, Needa and Sridhar, Srinivas},
title = {Nanomedicine Therapies for Pediatric Diseases},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2024},
doi = {10.1002/wnan.1996}
}
EUVIMED